From GlobeNewswire: 2025-06-20 16:15:00

NYSE American issued a warning to AIM ImmunoTech Inc. for not meeting the minimum stockholders’ equity requirements. The company had a stockholders’ deficit of $3.9 million as of March 31, 2025. AIM has until June 11, 2026 to regain compliance. The company’s common stock recommenced trading on the NYSE American on June 17, 2025. The warning does not affect the company’s business or operations. AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19, with their lead product Ampligen®. The company aims to regain compliance with NYSE American listing requirements.



Read more at GlobeNewswire: AIM ImmunoTech Announces NYSE American Notice of